MRI-TRUS Fusion Articles

BACKGROUND - Prostate biopsy supported by transperineal image fusion has recently been developed as a new method to the improve accuracy of prostate cancer detection.

OBJECTIVE - To describe the Ginsburg protocol for transperineal prostate biopsy supported by multiparametric magnetic resonance imaging (mpMRI) and transrectal ultrasound (TRUS) image fusion, provide learning points for its application, and report biopsy results.

To evaluate the efficacy of multiparametric magnetic resonance/transrectal ultrasound fusion (MRI/TRUS fusion) biopsy versus systematic biopsy and its association with PI-RADS v2 categories in patients with suspected prostate cancer.

To analyse the detection rates of primary MRI-fusion transperineal prostate biopsy using combined targeted and systematic core distribution in three tertiary referral centres.

Multicentre, prospective outcome study of 807 consecutive biopsy-naïve patients having undergone MRI-guided transperineal prostate biopsy as the first diagnostic intervention between 10/2012 and 05/2016.

To compare the detection rates of prostate cancer between systematic biopsy and targeted biopsy using a stereotactic robot-assisted transperineal prostate platform.

We identified consecutive men with suspicious lesion(s) on multi-parametric magnetic resonance imaging (mpMRI) who underwent both systematic and MRI-transrectal ultrasound (US) fusion targeted biopsy using our proprietary transperineal robot-assisted prostate biopsy platform between January 2015 to January 2019 at our institution for retrospectively analysis.

To assess cancer detection rates of different target-dependent transperineal magnetic resonance (MR) / ultrasound (US) fusion-guided biopsy templates with reduced number of systematic cores.

Single-centre outcome of transperineal MR/US fusion guided biopsies of 487 men with a single target MRI lesion, prospectively collected between 2012 and 2016.

The objective of this study was to test Prostate Imaging Reporting and Data System (PI-RADS) classification on multiparametric magnetic resonance imaging (mpMRI) and MRI-derived prostate-specific antigen density (PSAD) in predicting the risk of reclassification in men in active surveillance (AS), who underwent confirmatory or per-protocol follow-up biopsy.